5-amino-1mq research centers on its role as a selective, small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). By inhibiting NNMT, this research compound prevents the depletion of S-adenosylmethionine (SAM) and nicotinamide, elevating intracellular NAD+ levels and enhancing cellular energy expenditure. Preclinical studies evaluate 5-Amino-1MQ for its potential to alter adipocyte metabolism and mitochondrial dynamics in vitro and in animal models.
5-amino-1mq research centers on its role as a selective, small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). By inhibiting NNMT, this research compound prevents the depletion of S-adenosylmethionine (SAM) and nicotinamide, elevating intracellular NAD+ levels and enhancing cellular energy expenditure. Preclinical studies evaluate 5-Amino-1MQ for its potential to alter adipocyte metabolism and mitochondrial dynamics in vitro and in animal models.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a membrane-permeable, small-molecule quinolinium derivative that functions as a highly selective inhibitor of nicotinamide N-methyltransferase (NNMT). Discovered through high-throughput chemical screening and rational molecular optimization, 5-amino-1mq for research has emerged as a crucial molecular tool for investigating cytosolic enzyme kinetics, methyl group transfer, and cellular metabolic flux.
When laboratory scientists utilize a 5-amino-1mq research compound in experimental models, they isolate the precise biological consequences of NNMT suppression in cell culture systems and animal tissues. By preventing the breakdown of nicotinamide into 1-methylnicotinamide, the compound allows researchers to explore metabolic regulation without directly targeting upstream kinase cascades. Investigators seeking reference documentation can access our comprehensive PX1 research library hub to review structural properties and tissue-specific enzymatic expressions.
NNMT is a cytosolic enzyme responsible for methylating nicotinamide (NAM) using S-adenosylmethionine (SAM) as the universal methyl donor. This enzymatic reaction yields 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Because 1-MNA is rapidly excreted or further oxidized, hyperactive NNMT expression effectively drains NAM from the salvage pathway, reducing the total intracellular precursor pool required for conversion into nicotinamide mononucleotide (NMN) and nicotinamide adenine dinucleotide (NAD+).
In 5-amino-1mq research, application of this small-molecule inhibitor blocks the active catalytic site of NNMT with high kinetic affinity (IC50 in the low micromolar range). Blocking this enzymatic step preserves intracellular concentrations of both NAM and SAM. In vitro data indicate that preserving SAM levels maintains methyl donor availability for histone methyltransferases, influencing epigenetic regulation, while elevated NAM directly feeds into NAD+ biosynthesis pathways. Consequently, 5-amino-1mq research demonstrates marked increases in intracellular NAD+ content and elevated NAD+/NADH ratios, driving downstream sirtuin (SIRT1/SIRT3) activation and enhanced mitochondrial biogenesis.
The metabolic consequences of NNMT inhibition have been thoroughly documented across rodent models and immortalized cell lines. In mouse models of high-fat diet-induced obesity, an early 5-amino-1mq studie demonstrated that systemic administration resulted in decreased body weight gain, reduced white adipose tissue (WAT) mass, and significantly smaller adipocyte diameters without altering overall caloric intake.
Preclinical studies suggest that this phenotypic change is driven by an increase in basal metabolic rate and cellular energy expenditure within adipose tissue. In isolated adipocytes, exposure to 5-Amino-1MQ elevates oxygen consumption rate (OCR) and upregulates key markers of mitochondrial respiration, including uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). Furthermore, 5-amino-1mq research indicates that inhibiting NNMT prevents intracellular lipid droplet accumulation during preadipocyte differentiation. Researchers exploring metabolic pathways frequently analyze these mechanisms alongside specialized research peptides targeting mitochondrial function.
A critical question among academic and industrial research teams concerns the existence of a published 5-amino-1mq human clinical trial or formal human clinical trials or studies. To date, no verified 5-amino-1mq clinical trial human evaluation has been published in peer-reviewed medical literature, nor are there active clinical phase trials registered with global regulatory health authorities.
The entire published literature on 5-Amino-1MQ relies exclusively on in vitro assays, cell culture models, and preclinical rodent studies. Consequently, claims suggesting verified outcomes from 5-amino-1mq human trials or clinical studies represent misinterpretations of early-stage preclinical literature. Researchers utilizing the 5-amino-1mq research compound must treat the chemical strictly as an analytical tool designed for in vitro and preclinical laboratory research, where pharmacokinetic, toxicity, and dose-response parameters can be systematically defined.
Laboratory protocols evaluating NNMT inhibitors require precise compound preparation and solvent compatibility. While select bench studies reference 5-amino-1mq oral tablets research formulations for oral gavage models in rodents, high-purity crystalline powder remains the gold standard for controlled analytical experiments.
5-Amino-1MQ salts (typically iodide or chloride salts) exhibit distinct solubility characteristics depending on the solvent matrix. For cell culture experiments, dissolving raw 5-Amino-1MQ powder in dimethyl sulfoxide (DMSO) or sterile aqueous buffers ensures consistent micromolar concentrations without the analytical interference of tablet binders, fillers, or disintegrants. When evaluating solid oral dosage forms versus liquid reconstituted solutions in animal models, researchers must account for excipient binding, dissolution rates, and gastrointestinal absorption kinetics.
Scientific integrity and experimental reproducibility require rigorous quality verification of all chemical reagents. Every batch of 5-Amino-1MQ supplied for laboratory research must undergo multi-step analytical testing before deployment in cell culture or animal assays. A validated 5-amino-1mq test report should explicitly document purity percentage, molecular weight verification, and contaminant thresholds.
At PX1 Research, quality assurance relies on dual-testing protocols. Reverse-phase high-performance liquid chromatography (RP-HPLC) verifies chemical purity (>98%), ensuring the absence of synthetic intermediates. Electrospray ionization mass spectrometry (ESI-MS) confirms molecular weight and structural identity. Furthermore, because bacterial endotoxins can induce non-specific inflammatory responses in cellular models, chromogenic LAL testing ensures endotoxin levels remain under strict threshold limits (<0.01 EU/mg).
To establish clear baseline comparisons, researchers often evaluate 5-Amino-1MQ alongside other small molecules and peptides that target metabolic regulation and mitochondrial performance. While 5-Amino-1MQ operates via direct cytosolic NNMT inhibition, mitochondrial-derived peptides like MOTS-c regulate metabolic homeostasis by translocating to the nucleus during metabolic stress and modulating the folate-purine pathway.
In contrast, AMP-activated protein kinase (AMPK) activators such as AICAR stimulate cellular energy pathways by directly phosphorylating AMPK, completely bypassing the salvage pathway and SAM methyl donor kinetics. Meanwhile, synthetic peroxisome proliferator-activated receptor delta (PPAR-δ) agonists like GW501516 alter transcriptional programs governing fatty acid oxidation in skeletal muscle. Comparing 5-Amino-1MQ to these reference compounds highlights its unique dual action: increasing intracellular NAD+ availability while preserving cellular SAM methyl pools for epigenetic regulation.
Maintaining chemical stability is essential for acquiring valid experimental data. Lyophilized or solid 5-Amino-1MQ powder should be stored at -20°C in a desiccated, light-protected environment. The compound exhibits sensitivity to prolonged exposure to light and ambient atmospheric moisture.
For in vitro reconstitution, solid powder should be dissolved in sterile DMSO or high-purity laboratory water to create concentrated stock solutions. Reconstituted solutions should be aliquoted into single-use microcentrifuge tubes and stored at -80°C to eliminate repeated freeze-thaw cycles. Prior to treating cell cultures, stock solutions must be diluted directly into culture media, ensuring final DMSO concentrations remain under 0.1% (v/v) to avoid vehicle-induced cellular toxicity.
Assay consistency depends entirely on raw material purity. PX1 Research synthesizes research compounds in USA-based, GMP-compliant facilities adhering to ISO 17025 laboratory testing standards. Every lot of 5-Amino-1MQ is accompanied by a lot-specific Certificate of Analysis (COA) detailing HPLC purity assays, mass spectrometry spectra, and endotoxin verification.
With distribution centers in California and Arizona, PX1 Research provides same-day shipping (Monday through Friday) for orders placed before cutoff times, ensuring minimal transit delays for temperature-sensitive reagents. Institutional laboratories, contract research organizations (CROs), and university departments requiring bulk allocations can register for wholesale lab accounts to access volume pricing and lot reservation services.
What is 5 amino 1mq research primarily focused on?
5 amino 1mq research focuses on evaluating selective inhibition of nicotinamide N-methyltransferase (NNMT), examining how blocking this enzyme preserves cellular NAD+ precursor pools, alters SAM:SAH methyl ratios, and enhances cellular energy expenditure in preclinical models.
How does 5-amino-1mq research differ from general NAD+ booster studies?
Unlike direct NAD+ precursors that feed directly into salvage pathways, 5-amino-1mq research investigates the prevention of NAD+ degradation by selectively inhibiting the NNMT enzyme, thereby preventing the destruction of nicotinamide and preserving intracellular SAM.
Why is 5-amino-1mq for research distributed strictly as a chemical reagent?
5-amino-1mq for research is an unapproved small-molecule inhibitor intended exclusively for in vitro enzymatic assays and preclinical animal research. It is not licensed, approved, or formulated for human or veterinary medical use.
What defines a high-purity 5-amino-1mq research compound?
A high-purity 5-amino-1mq research compound is characterized by RP-HPLC purity exceeding 98%, mass spectrometry identity confirmation, and low endotoxin levels (<0.01 EU/mg) verified via lot-specific independent laboratory COAs.
What did early rodent 5-amino-1mq studie protocols reveal regarding adipocytes?
Early rodent 5-amino-1mq studie protocols demonstrated that NNMT inhibition reduced white adipose tissue mass, reduced adipocyte cell volume, and elevated basal metabolic rates without decreasing daily food consumption.
Are there published datasets for a 5-amino-1mq clinical trial human cohort?
No. There are currently no published datasets or completed studies for any 5-amino-1mq clinical trial human cohort in peer-reviewed literature. All existing data stems from in vitro assays and rodent models.
Has a 5-amino-1mq human clinical trial been approved by regulatory agencies?
No regulatory agency has approved a 5-amino-1mq human clinical trial. The compound remains in early-stage preclinical investigation for basic science research.
Where can scientists find 5-amino-1mq human clinical trials or studies data?
There are no legitimate 5-amino-1mq human clinical trials or studies available. Researchers should rely strictly on peer-reviewed preclinical literature focusing on cellular NNMT kinetics and rodent energy expenditure models.
Why are claims regarding 5-amino-1mq human trials inaccurate?
Claims regarding 5-amino-1mq human trials are inaccurate because the compound has not progressed past preclinical rodent safety and efficacy screening. No human phase 1, 2, or 3 trial data exists.
What is the status of 5-amino-1mq human trials or clinical studies in global databases?
A search of international clinical trial registries reveals zero active or completed 5-amino-1mq human trials or clinical studies. The compound is designated exclusively for laboratory research.
How is 5-amino-1mq oral tablets research evaluated in laboratory settings?
5-amino-1mq oral tablets research evaluates solid dosage forms in animal oral gavage studies to measure pharmacokinetics, though raw crystalline powder dissolved in DMSO or sterile water remains preferred for precise in vitro testing.
What information must be present on a 5-amino-1mq test report?
A valid 5-amino-1mq test report must include RP-HPLC chromatograms showing >98% purity, ESI-MS mass spectrum matching theoretical molecular weight, and chromogenic LAL assay verification of low endotoxin content.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.